Ad is loading...
RMFCX
Price
$58.23
Change
-$0.50 (-0.85%)
Updated
Nov 15 closing price
TRLWX
Price
$23.90
Change
-$0.06 (-0.25%)
Updated
Nov 15 closing price
Ad is loading...

RMFCX vs TRLWX

Header iconRMFCX vs TRLWX Comparison
Open Charts RMFCX vs TRLWXBanner chart's image
American Funds American Mutual R3
Price$58.23
Change-$0.50 (-0.85%)
VolumeN/A
CapitalizationN/A
Nuveen Large Cap Value W
Price$23.90
Change-$0.06 (-0.25%)
VolumeN/A
CapitalizationN/A
RMFCX vs TRLWX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RMFCX vs. TRLWX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMFCX is a StrongBuy and TRLWX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 104B vs. TRLWX (7.11B). TRLWX pays higher dividends than RMFCX: TRLWX (1.98) vs RMFCX (1.69). RMFCX was incepted earlier than TRLWX: RMFCX (22 years) vs TRLWX (6 years). RMFCX is a more actively managed with annual turnover of: 25.00 vs. TRLWX (23.00). TRLWX has a lower initial minimum investment than RMFCX: TRLWX (0) vs RMFCX (250). RMFCX (21.31) and TRLWX (20.29) have marching annual gain over last year. RMFCX (44.92) and TRLWX (43.36) have equivalent 5 years return.
RMFCXTRLWXRMFCX / TRLWX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence22 years6 years-
Gain YTD16.44019.79983%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets104B7.11B1,464%
Annual Yield % from dividends1.691.9886%
Returns for 1 year21.3120.29105%
Returns for 3 years15.465.47282%
Returns for 5 years44.9243.36104%
Returns for 10 years65.01N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNTS0.630.01
+1.10%
Momentus
WWW21.79-0.24
-1.09%
Wolverine World Wide
SNAP10.60-0.16
-1.49%
Snap
SHC14.31-0.68
-4.54%
Sotera Health Company
ENTA9.53-0.60
-5.92%
Enanta Pharmaceuticals